Treating Precancerous Lesions Requiring SRT: What to Expect From Superficial Radiation Therapy

Expert Evaluation and Evidence-Based Management

When a skin lesion is identified as precancerous or early-stage cancerous and surgery is not the preferred option, superficial radiation therapy (SRT) offers a highly effective, non-surgical path to treatment. For patients dealing with skin lesions in areas where surgical excision would be technically complex, cosmetically challenging, or medically inadvisable, SRT provides a clinically proven alternative that can be performed entirely in a dermatology office setting.

SRT is not a new or experimental technology. It has been used in dermatology for decades and has a well-established record of effectiveness for appropriate candidates. Whether you are managing a confirmed precancerous lesion or an early-stage non-melanoma skin cancer and your dermatologist has recommended SRT as the right treatment approach, understanding what the process involves puts you in a better position to move forward with confidence.

In this guide, we break down what superficial radiation therapy is, which lesions it is used to treat, what the treatment course looks like, what results to expect, and how Connolly Dermatology guides patients through the entire process.

What Are Precancerous Lesions and Why Do They Require SRT?

Precancerous skin lesions are abnormal skin growths that have not yet become invasive cancers but carry a meaningful risk of progressing to skin cancer if left untreated. In addition to truly precancerous lesions, SRT is also used for early-stage, non-invasive, or low-risk non-melanoma skin cancers where non-surgical treatment is preferred.

The most common lesion types appropriate for SRT include:

• ·         Bowen’s Disease (Squamous Cell Carcinoma In Situ): A precancerous or very early-stage form of squamous cell carcinoma confined to the outermost layer of the skin. It appears as a red, scaly, persistent patch and carries a risk of progression to invasive SCC if not treated.
• ·         Superficial Basal Cell Carcinoma (sBCC): The most superficial subtype of BCC, appearing as a flat, red, slightly scaly lesion most often on the trunk. SRT is an effective option for superficial BCC, particularly in older patients or when the lesion is located where surgery would be difficult.
• ·         Nodular Basal Cell Carcinoma: The most common BCC subtype, presenting as a pearly or translucent nodule. SRT is an established treatment option for nodular BCC in appropriate candidates.
• ·         Well-Differentiated Squamous Cell Carcinoma (Low-Risk SCC): Early-stage, low-risk SCC without deep invasion or perineural involvement may be treated with SRT, particularly in patients who are not surgical candidates or when the lesion is in a location where surgery would produce significant functional or cosmetic morbidity.
• ·         Actinic Keratoses (Selected Cases): While most actinic keratoses are managed with cryotherapy or topical treatments, recalcitrant field disease in patients who are appropriate SRT candidates may in select cases benefit from radiation-based approaches.

Risk factors for developing precancerous lesions and lesions requiring SRT include:

• ·         Cumulative UV Exposure: Decades of sun exposure is the dominant driver of actinic keratoses, Bowens disease, BCC, and SCC. Most lesions requiring SRT appear on chronically sun-exposed skin.
• ·         Fair Skin and Light Coloring: Reduced melanin protection increases lifetime UV damage accumulation and skin cancer risk.
• ·         Advanced Age: The incidence of all non-melanoma skin cancers and precancerous lesions increases significantly with age as cumulative UV damage compounds over decades.
• ·         Immunosuppression: Transplant recipients and patients on long-term immunosuppressive medications are at markedly elevated risk for SCC and Bowens disease.
• ·         Prior Skin Cancer History: A personal history of any skin cancer substantially increases the risk of developing additional lesions.
• ·         Chronic Radiation or Chemical Exposure: Prior history of certain occupational or medical exposures can increase skin cancer risk over time.

Why Some Lesions Are Better Suited to SRT Than Surgical Treatment

Surgery is the most common treatment for non-melanoma skin cancers, but it is not always the most appropriate choice for every patient or every lesion. SRT is a preferred or highly reasonable alternative in the following situations:

• ·         The lesion is located in an area where surgery would be technically difficult, produce significant scarring, or risk functional impairment (such as the nose, ears, eyelids, or lower legs)
• ·         The patient is elderly, has medical comorbidities, or is on anticoagulant therapy that increases surgical risk
• ·         The patient prefers a non-surgical approach and is an appropriate candidate
• ·         Prior surgery in the same area has left tissue with poor healing potential

For patients who meet these criteria, SRT offers cure rates that are comparable to surgical approaches for appropriate lesion types, without the recovery period associated with excision.

Confirm the Diagnosis Before Starting SRT

A biopsy confirming the type, subtype, and extent of the lesion is required before SRT is initiated. Beginning radiation therapy without a confirmed pathological diagnosis is not appropriate, as the treatment course is tailored specifically to the lesion type. The pre-treatment evaluation for SRT typically includes:

• ·         Biopsy Confirmation: A punch, shave, or excisional biopsy confirms the lesion type and subtype. The pathology report guides the radiation treatment protocol, fractionation schedule, and margin planning.
• ·         Lesion Measurement and Mapping: The clinical dimensions of the lesion are measured carefully to determine the appropriate treatment field size and to plan shielding that protects surrounding normal tissue.
• ·         Lesion Depth Assessment: Superficial radiation therapy delivers radiation to a limited depth, making it appropriate for superficial and early-stage lesions. Deeper, more invasive lesions with subcutaneous involvement may not be appropriate SRT candidates.
• ·         Patient Health and Medication Review: Certain medical conditions, medications, and prior radiation history at the same site affect whether SRT is appropriate and how the treatment plan should be structured.
• ·         Photographic Documentation: Baseline photographs of the lesion and treatment site are taken to track clinical response throughout the treatment course.

This comprehensive pre-treatment evaluation ensures that SRT is the right approach for your specific lesion before the first treatment session begins.

Treating Precancerous Lesions Requiring SRT: Treatment Options Compared

SRT is the central treatment being discussed on this page, but it is important to understand where SRT fits within the broader landscape of treatment options for precancerous and early-stage skin lesions. The right approach depends on the lesion type, size, location, depth, patient health, and patient preference.

Superficial Radiation Therapy (SRT)

Superficial radiation therapy delivers low-energy X-rays to a precisely targeted area of skin, penetrating just deep enough to reach the lesion while minimizing exposure to surrounding healthy tissue and underlying structures. Treatment is delivered in a series of short sessions (fractions), typically 2 to 3 times per week over the course of 3 to 6 weeks depending on the lesion type and protocol. Each session takes only a few minutes of actual radiation delivery time. No anesthesia is required and patients experience no pain during the treatment itself.

Tips to support a successful SRT course:

• ·         Attend every scheduled session, as consistent fractionation is critical to achieving the intended cumulative dose
• ·         Keep the treatment site clean and protected as directed between sessions
• ·         Avoid applying any topical products to the treatment site unless approved by your dermatologist
• ·         Protect the treated area from sun exposure throughout and after the treatment course

Electronic Brachytherapy

Electronic brachytherapy (eBT) is a form of surface radiation therapy that uses a high-dose-rate applicator placed directly on the skin to deliver precisely targeted radiation from above the lesion surface. Like SRT, it is a non-surgical, in-office treatment for superficial skin cancers and selected precancerous lesions. Electronic brachytherapy delivers treatment in fewer fractions than traditional SRT and may be appropriate for lesions in locations where conventional SRT applicator geometry presents technical challenges.

Surgical Excision

Standard surgical excision removes the lesion with a margin of surrounding normal tissue and provides tissue for pathological margin assessment. Excision is preferred for deeper, higher-risk, or recurrent lesions and for patients who are good surgical candidates. It is less suitable for patients with significant surgical risk factors, anticoagulation therapy, or lesions in anatomically sensitive locations where excision would cause significant cosmetic or functional morbidity.

Mohs Micrographic Surgery

Mohs surgery offers the highest cure rate for high-risk, recurrent, or anatomically challenging non-melanoma skin cancers. Tissue is examined in real time during the procedure until clear margins are confirmed. Mohs is the preferred approach for high-risk SCC, morpheaform or infiltrative BCC, and lesions in cosmetically critical areas such as the nose, eyelids, and lips. It is not applicable to patients for whom surgical excision is contraindicated.

Topical and Destructive Treatments for Precancerous Lesions

For truly precancerous lesions such as actinic keratoses and superficial Bowens disease, topical prescription treatments (fluorouracil cream, imiquimod) and in-office destructive methods (cryotherapy, photodynamic therapy, ED&C) are commonly used first-line options. These approaches are generally appropriate for lesions that do not yet require the tissue-targeted precision of SRT or surgery, and they may be used alongside or prior to SRT for patients with widespread field disease.

Quick Comparison Table

Timeline And Expectations: How Long Treatment Takes

When undergoing SRT for a precancerous or early-stage skin lesion, understanding the treatment course and what to expect at each stage helps patients plan ahead and recognize what a normal response looks like.

Before Treatment Begins: Biopsy results are reviewed, the lesion is measured and mapped, and the treatment protocol is established. Baseline photographs are taken. Most patients begin their first SRT session within 1 to 2 weeks of completing the pre-treatment evaluation.

During the Treatment Course (Weeks 1 to 6): SRT is delivered in fractions, typically 2 to 3 times per week for 3 to 6 weeks. As treatment progresses, the treated area may become red, tender, or develop a superficial crust, which is a normal inflammatory response indicating that the radiation is working. Most patients maintain their normal daily activities throughout the treatment course.

Weeks 4 to 8 Post-Treatment: The treated site completes its initial healing response. Redness and crusting resolve and the skin begins to resurface. The treated area may appear temporarily lighter or pinker than the surrounding skin.

Months 3 to 6 Post-Treatment: The skin at the treatment site continues to mature and normalize. A follow-up evaluation is typically scheduled at 3 months post-treatment to assess the clinical response and confirm clearance of the treated lesion.

Months 6 to 12+ (Long-Term Monitoring): Regular follow-up skin exams continue to monitor for any signs of recurrence at the treated site and to identify new lesions elsewhere. Annual or semiannual full-body skin exams are recommended for patients with a history of skin cancer or precancerous lesions.

Preventing New Lesions After SRT

SRT addresses the treated lesion, but ongoing sun protection and skin monitoring are essential for preventing new precancerous lesions and skin cancers from developing. Here are key steps to protect your skin after completing SRT:

• Apply broad-spectrum SPF 30 or higher sunscreen daily, including on cloudy days and during winter months
• Wear protective clothing, wide-brimmed hats, and UV-blocking sunglasses when outdoors
• Avoid peak UV exposure hours between 10 a.m. and 4 p.m. when possible
• Avoid tanning beds entirely
• Schedule regular full-body skin exams with your dermatologist, typically every 6 to 12 months depending on your risk profile
• Perform monthly self-skin checks at home and report any new or changing lesions promptly
• Protect the treated site from sun exposure during and after the treatment course, as radiation-treated skin may be more sensitive to UV

How Connolly Dermatology Helps With Treating Precancerous Lesions Requiring SRT

At Connolly Dermatology, we take a clinical, comprehensive approach to the evaluation and treatment of precancerous and early-stage skin lesions. We do not guess. We confirm every diagnosis through biopsy before recommending SRT, assess each lesion carefully to determine whether SRT is the most appropriate treatment option, and build a treatment protocol tailored to your specific lesion, location, and health profile.

If you have been told you have a precancerous lesion or a skin cancer that may require SRT, or if you would like an evaluation of a lesion that concerns you, our team is here to guide you through every step of the process. Book an appointment with Connolly Dermatology today.